title: Cytoskeletal modulators and pleiotropic strategies for Alzheimer drug discovery.
abstract: The Alzheimer's Association Research Roundtable, a consortium of Association senior scientists and leaders from pharmaceutical, biotech, and imaging companies, met to discuss strategies for developing novel therapeutics for the treatment of Alzheimer's disease (AD). The goal of the meeting was to address, primarily, strategies that do not hinge on directly modulating levels of beta-amyloid. The identification of beta-amyloid as the major constituent of senile plaques and the subsequent discovery that familial AD can be caused by mutations in either the beta-amyloid precursor protein or presenilins, proteases that cleaves beta-amyloid from its precursor, has spawned numerous therapeutic strategies for treating AD. These include passive and active vaccines for clearing beta-amyloid from the brain and the development of small molecule inhibitors of beta- and gamma-secretases that can attenuate the production of beta-amyloid. But the field recognizes that there is more to AD than beta-amyloid alone. What role do neurofibrillary tangles play in the disease, for example, and how are they influenced by beta-amyloid? What lies upstream of beta-amyloid production in the sporadic AD brain, and how do apolipoproteins and cholesterol influence disease progression? Are there environmental or behavioral factors that contribute to the initiation or progression of sporadic AD? Because of the complexity of AD, the field is continually looking to other therapeutic strategies that may complement or substitute for therapies that target beta-amyloid. This roundtable meeting was charged with discussing and evaluating some of those strategies.
authors: Elan Pharmaceuticals, 800 Gateway Boulevard, South San Francisco, CA 94080, USA. Dale.schenk@elan.com
authors: Dale
authors: D
authors: Schenk
authors: Maria C
authors: MC
authors: Carrillo
authors: John Q
authors: JQ
authors: Trojanowski